Record Details

Plant active metabolites: A new paradigm in the treatment of Hypertension (a brief description of Indian Pharmacopoeia – 2022 herbal monographs)

NOPR - NISCAIR Online Periodicals Repository

View Archive Info
 
 
Field Value
 
Title Plant active metabolites: A new paradigm in the treatment of Hypertension (a brief description of Indian Pharmacopoeia – 2022 herbal monographs)
 
Creator Tiwari, Ritu
Mishra, Smita
Kumar, Amit
D, Gnanbhaskar
Kalaiselvan, V.
 
Subject Clinical efficacy
Herbal monographs
Hypertension
Indian Pharmacopoeia-2022
Marker compounds
 
Description 210-218
Hypertension is a significant public health problem worldwide. Nearly two-thirds of all hypertensive patients live in developing and under-developed countries, creating a considerable burden of hypertension. India is among the countries which spend more than one-third of all income on cardiovascular diseases and hypertension. Although several modern medications are available to control the disease symptoms, their expense and side effects restrict their public use. More than 80% of the world's population relies on traditional treatment, which is used recklessly without any restrictions or proof thereof. Indian Pharmacopoeia is working diligently towards standardising herbal drugs and plant-derived pharmaceuticals, i.e., Phyto-pharmaceuticals, to regulate their usage. The present article focuses on the standardisation of marker compoundsof different indigenous anti-hypertensive medicinal plants, which can be used as bioactive markers in phytopharmaceuticaldrug development. The study includes consolidated information about the important anti-hypertensive biomarkers and theiridentification and assay methodology.
 
Date 2023-07-31T10:16:23Z
2023-07-31T10:16:23Z
2023-07
 
Type Article
 
Identifier 0976-0512 (Online); 0976-0504 (Print)
http://nopr.niscpr.res.in/handle/123456789/62390
https://doi.org/10.56042/ijnpr.v14i2.1505
 
Language en
 
Relation A61K 36/00, A61P 9/00
 
Publisher NIScPR-CSIR, India
 
Source IJNPR Vol.14(2) [June 2023]